Commerce Bank reduced its stake in shares of Celgene Corp. (NASDAQ:CELG) by 4.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 163,992 shares of the biopharmaceutical company’s stock after selling 8,028 shares during the period. Commerce Bank’s holdings in Celgene Corp. were worth $17,142,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of CELG. Park National Corp OH raised its position in Celgene Corp. by 0.4% in the third quarter. Park National Corp OH now owns 3,158 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 12 shares in the last quarter. Proficio Capital Partners LLC raised its position in Celgene Corp. by 0.9% in the third quarter. Proficio Capital Partners LLC now owns 1,627 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 15 shares in the last quarter. Jolley Asset Management LLC raised its position in Celgene Corp. by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 25 shares in the last quarter. Integrated Wealth Management raised its position in Celgene Corp. by 1.5% in the third quarter. Integrated Wealth Management now owns 1,689 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 25 shares in the last quarter. Finally, Eads & Heald Investment Counsel raised its position in Celgene Corp. by 0.3% in the third quarter. Eads & Heald Investment Counsel now owns 7,699 shares of the biopharmaceutical company’s stock valued at $805,000 after buying an additional 25 shares in the last quarter. Institutional investors and hedge funds own 76.43% of the company’s stock.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) traded down 1.82% on Wednesday, reaching $119.91. 1,575,848 shares of the company’s stock were exchanged. Celgene Corp. has a 52-week low of $93.05 and a 52-week high of $127.00. The stock has a market cap of $92.95 billion, a P/E ratio of 45.54 and a beta of 1.71. The company’s 50 day moving average price is $108.88 and its 200-day moving average price is $106.73.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.48 by $0.10. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The firm earned $2.98 billion during the quarter, compared to analyst estimates of $2.84 billion. During the same period last year, the company earned $1.23 EPS. Celgene Corp.’s quarterly revenue was up 27.8% compared to the same quarter last year. Equities analysts forecast that Celgene Corp. will post $5.92 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/30/celgene-corp-celg-shares-sold-by-commerce-bank.html.

CELG has been the topic of several analyst reports. Vetr upgraded shares of Celgene Corp. from a “hold” rating to a “buy” rating and set a $129.47 price target on the stock in a research note on Monday, November 21st. Cann initiated coverage on shares of Celgene Corp. in a research note on Monday. They set an “outperform” rating and a $141.00 price target on the stock. Oppenheimer Holdings Inc. initiated coverage on shares of Celgene Corp. in a research note on Tuesday. They set an “outperform” rating and a $141.00 price target on the stock. Zacks Investment Research upgraded shares of Celgene Corp. from a “hold” rating to a “buy” rating and set a $130.00 price target on the stock in a research note on Friday, August 5th. Finally, BTIG Research upgraded shares of Celgene Corp. from a “neutral” rating to a “buy” rating and increased their price target for the stock from $116.14 to $138.00 in a research note on Wednesday, August 3rd. Four analysts have rated the stock with a hold rating and twenty-seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $136.62.

In other Celgene Corp. news, Director Richard W. Barker sold 20,000 shares of Celgene Corp. stock in a transaction on Friday, September 23rd. The stock was sold at an average price of $110.82, for a total transaction of $2,216,400.00. Following the completion of the sale, the director now directly owns 31,332 shares of the company’s stock, valued at approximately $3,472,212.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Corp /De/ Celgene bought 800,150 shares of the firm’s stock in a transaction on Monday, October 24th. The shares were purchased at an average cost of $14.00 per share, with a total value of $11,202,100.00. The disclosure for this purchase can be found here. Corporate insiders own 0.97% of the company’s stock.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.